Perioperative Pembrolizumab Plus Chemotherapy Should Be Recommended
For this 45-year-old woman with stage IIIA, node-positive, PD-L1-negative triple-negative breast cancer, perioperative pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improves both event-free survival and overall survival regardless of PD-L1 status and represents the current standard of care. The answer is B.
Evidence Supporting This Recommendation
The KEYNOTE-522 trial demonstrated a statistically significant overall survival benefit at the final analysis (median follow-up 75.1 months). The 60-month OS was 86.6% in the pembrolizumab-chemotherapy group versus 81.7% in the placebo-chemotherapy group (P = 0.002) 1. This OS benefit occurred regardless of PD-L1 expression status, making PD-L1 testing unnecessary for treatment decisions in this setting.
The Standard Regimen
Current guidelines designate the KEYNOTE-522 regimen as Category 1 for stage II-III TNBC 2. The treatment consists of:
- Neoadjuvant phase: Pembrolizumab 200 mg every 3 weeks for 4 cycles with paclitaxel and carboplatin, followed by 4 cycles with doxorubicin/epirubicin and cyclophosphamide
- Surgery: Definitive surgical resection
- Adjuvant phase: Pembrolizumab 200 mg every 3 weeks for up to 9 cycles
Why PD-L1 Status Doesn't Matter Here
The trial enrolled patients regardless of tumor PD-L1 expression 3. Both the NCCN and ESMO guidelines explicitly state that pembrolizumab benefit in early-stage TNBC is independent of PD-L1 status 2. This contrasts sharply with metastatic TNBC, where PD-L1 CPS ≥10 is required for pembrolizumab approval.
Node-Positive Disease Is an Indication, Not a Contraindication
This patient's node-positive status actually strengthens the indication for pembrolizumab. The trial specifically enrolled high-risk patients (tumor >2 cm regardless of nodal status, or >1-2 cm with nodal involvement) 1. Answer D is incorrect—there is no restriction to node-negative disease, and T-DXd is not indicated in the early-stage curative setting.
Common Pitfalls to Avoid
Do not withhold pembrolizumab based on PD-L1-negative status. This is a critical error that would deny this patient a proven survival benefit. The PD-L1 requirement only applies to metastatic TNBC treated with pembrolizumab plus chemotherapy 3.
Do not use pembrolizumab only in the adjuvant setting (Answer E is wrong). The KEYNOTE-522 regimen requires both neoadjuvant and adjuvant pembrolizumab administration. The trial design included pembrolizumab throughout the perioperative period, and this complete regimen is what demonstrated the OS benefit 1.
Do not assume pCR alone is sufficient (Answer C is incorrect). While the trial did show improved pCR rates (63.0% vs 55.6%), the critical finding is the demonstrated OS benefit at 7-year follow-up, not just surrogate endpoints 1.
Safety Considerations
The patient's lack of autoimmune history makes her an appropriate candidate. The KEYNOTE-522 trial excluded patients with active autoimmune disease requiring systemic therapy within 2 years or conditions requiring immunosuppression 3. Treatment-related adverse events were consistent with established safety profiles, with permanent discontinuation occurring in 16% of patients in the combination arm 3.
Alternative Considerations
The anthracycline-free regimen (docetaxel/carboplatin/pembrolizumab) is listed as "useful in certain circumstances" by NCCN 2, but for this node-positive patient, the full KEYNOTE-522 regimen with anthracyclines remains preferred, as the anthracycline-free approach showed lower pCR rates particularly in node-positive disease (45% vs 65% in node-negative) 2.